Published in Br J Dermatol on September 01, 1990
Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol (2006) 1.18
COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol (2003) 0.98
Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol (2011) 0.97
Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc Natl Acad Sci U S A (2008) 0.94
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest Ophthalmol Vis Sci (2009) 0.94
Cyclooxygenase-1 and -2 are expressed by human T cells. Clin Exp Immunol (1999) 0.90
Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. J Virol (2004) 0.86
A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. J Pain Res (2017) 0.75
Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc Natl Acad Sci U S A (1986) 4.92
Control of ribonucleic acid function by oligonucleoside methylphosphonates. Biochimie (1986) 2.43
The association of genital herpesvirus with cervical atypia and carcinoma in situ. Am J Epidemiol (1970) 2.17
First aid treatment of jellyfish stings in Australia. Response to a newly differentiated species. Med J Aust (1993) 2.01
Tumorigenic transformation induced by a specific fragment of DNA from herpes simplex virus type 2. Proc Natl Acad Sci U S A (1980) 1.66
Virus-specific immunity in neonatal and adult mouse rotavirus infection. Infect Immun (1983) 1.60
Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc Natl Acad Sci U S A (1989) 1.54
The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J Virol (2002) 1.54
Partial purification of box jellyfish (Chironex fleckeri) nematocyst venom isolated at the beachside. Toxicon (1998) 1.44
Fulminant hepatic failure from a sea anemone sting. Ann Intern Med (1994) 1.43
Jellyfish envenomation syndromes. J Am Acad Dermatol (1986) 1.43
The chemistry and toxicology of some venomous pelagic coelenterates. Toxicon (1977) 1.33
Antibody to genital herpes simplex virus: association with cervical atypia and carcinoma in situ. J Natl Cancer Inst (1970) 1.32
Immunofluorescent detection of herpesvirus antigens in exfoliated cells from human cervical carcinoma. Proc Natl Acad Sci U S A (1970) 1.25
Immunity to herpes simplex virus type 2. IV. Impaired lymphokine production during recrudescence correlates with an imbalance in T lymphocyte subsets. J Immunol (1982) 1.24
Prevention of rotavirus-induced diarrhea in neonatal mice born to dams immunized with empty capsids of simian rotavirus SA-11. J Infect Dis (1984) 1.23
Possible role of Herpesvirus hominis, type 2, in human cervical cancer. Fed Proc (1973) 1.22
Proteins of herpesvirus type 2: I. Virion, nonvirion, and antigenic polypeptides in infected cells. Virology (1976) 1.21
Teledermatology and in-person examinations: a comparison of patient and physician perceptions and diagnostic agreement. Arch Dermatol (1998) 1.21
Prophylactic antibiotics in hip fractures. A double-blind, prospective study. J Bone Joint Surg Am (1980) 1.18
The role of normal skin in the spread of streptococcal pyoderma. J Hyg (Lond) (1970) 1.18
Herpesvirus type 2 isolated from cervical tumor cells grown in tissue culture. Science (1971) 1.17
Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J Virol (1989) 1.17
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol (1999) 1.14
Antibody to HSV-2 induced tumor specific antigens in serums from patients with cervical carcinoma. Science (1973) 1.12
Erythema multiforme lesions are associated with expression of a herpes simplex virus (HSV) gene and qualitative alterations in the HSV-specific T-cell response. Br J Dermatol (1998) 1.12
Immunity to herpes simplex virus type 2: recurrent lesions are associated with the induction of suppressor cells and soluble suppressor factors. Infect Immun (1983) 1.09
Angiolymphoid hyperplasia with eosinophilia. Arch Dermatol (1978) 1.08
Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir Chem Chemother (1999) 1.07
Neoplastic transformation of cultured Syrian hamster embryo cells by DNA of herpes simplex virus type 2. J Virol (1979) 1.05
Demonstration by plaque reduction technique of immunologic relationship between canine herpes virus and herpes simplex virus. Proc Soc Exp Biol Med (1968) 1.05
Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J Virol (1989) 1.04
Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Biophys Res Commun (1994) 1.04
Immortalization and neoplastic transformation of normal diploid cells by defined cloned DNA fragments of herpes simplex virus type 2. Proc Natl Acad Sci U S A (1983) 1.04
A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli. J Biol Chem (1991) 1.02
Viruses and gynecologic cancers: herpesvirus protein (ICP 10/AG-4), a cervical tumor antigen that fulfills the criteria for a marker of carcinogenicity. Cancer (1981) 0.99
The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J Virol (1998) 0.99
Cutaneous tuberculosis. J Am Acad Dermatol (1982) 0.98
Use of the radioallergosorbent test for the study of coelenterate toxin-specific immunoglobulin E. Int Arch Allergy Appl Immunol (1980) 0.97
Longitudinal study of a patient with herpes-simplex-virus-associated erythema multiforme: viral gene expression and T cell repertoire usage. Dermatology (1999) 0.97
Immunity to herpes simplex virus type 2: cell-mediated immunity in latently infected guinea pigs. Infect Immun (1980) 0.97
Ultrastructural characterization of the Molluscum contagiosum virus genome. Virology (1977) 0.97
Immunodiagnostic potential of a virus-coded, tumor-associated antigen (AG-4) in cervical cancer. Cancer (1977) 0.97
Herpesvirus type 2-related antigens and their relevance to humoral and cell-mediated immunity in patients with cervical cancer. Cancer Res (1976) 0.96
Characterization of Candida albicans epidermolytic proteases and their role in yeast-cell adherence to keratinocytes. Clin Exp Dermatol (1990) 0.96
Jellyfish envenomation syndromes updated. Ann Emerg Med (1987) 0.96
Traveler's diarrhea associated with rotavirus infection: analysis of virus-specific immunoglobulin classes. Infect Immun (1981) 0.95
Recurrent cutaneous jellyfish eruptions without envenomation. Acta Derm Venereol (1985) 0.95
Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis (1987) 0.94
Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E. Am J Pathol (1979) 0.94
Proteins of herpesvirus type 2. III. Isolation and immunologic characterization of a large molecular weight viral protein. Virology (1978) 0.94
Adverse effects of isotretinoin therapy. Cutis (1984) 0.94
Reactivation of herpes simplex virus is associated with production of a low molecular weight factor that inhibits lymphokine activity in vitro. J Immunol (1987) 0.94
The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther (2009) 0.94
Multistep transformation by defined fragments of herpes simplex virus type 2 DNA: oncogenic region and its gene product. Proc Natl Acad Sci U S A (1985) 0.93
The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity. Virology (1997) 0.93
Proteins of herpesvirus type 2. II. Studies demonstrating a correlation between a tumor-associated antigen (AG-4) and a virion protein. Virology (1976) 0.92
One Linuche mystery solved: all 3 stages of the coronate scyphomedusa Linuche unguiculata cause seabather's eruption. J Am Acad Dermatol (2001) 0.92
Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions. J Invest Dermatol (1997) 0.92
Anaphylaxis after contact with a jellyfish. J Allergy Clin Immunol (1985) 0.91
ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). J Biol Chem (1996) 0.91
Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5. Antiviral Res (1993) 0.91
Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine (2002) 0.91
Fatal envenomation by Chironex fleckeri, the north Australian box jellyfish: the continuing search for lethal mechanisms. Med J Aust (1988) 0.90
First aid for jellyfish envenomation. South Med J (1983) 0.90
A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine (2001) 0.90
The transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J Biol Chem (1992) 0.90
Cell-mediated immunity to cytomegalovirus (CMV) and herpes simplex virus (HSV) antigens in the acquired immune deficiency syndrome: interleukin-1 and interleukin-2 modify in vitro responses. J Clin Immunol (1984) 0.89
Fatal Portuguese man-o'-war (Physalia physalis) envenomation. Ann Emerg Med (1989) 0.89
Local skin reaction caused by the plastic catheter tubing of the continuous subcutaneous insulin infusion system. Cutis (1988) 0.89
Inhibition of herpes simplex virus replication by antisense oligo-2'-O-methylribonucleoside methylphosphonates. Biochemistry (1995) 0.89
Expression and cellular compartmentalization of a herpes simplex virus type 2 protein (ICP 10) in productively infected and cervical tumor cells. Cancer Invest (1983) 0.89
An approach to chemotherapy based on base sequence information and nucleic acid chemistry. Matagen (masking tape for gene expression). Ann N Y Acad Sci (1987) 0.89
Kaposi's varicelliform eruption complicating pemphigus foliaceus. Arch Dermatol (1967) 0.88
Biologic and immunologic comparison of two HSV-2 variants: one an isolate from cervical tumor cells. Arch Gesamte Virusforsch (1974) 0.88
Immunity to herpes simplex virus: virus reactivation modulates lymphokine activity. J Infect Dis (1985) 0.88
Cutaneous ultraviolet radiation inhibits herpes simplex virus-induced lymphoproliferation in latently infected subjects. Clin Immunol Immunopathol (1994) 0.88
Experimental study of the disease of the corneal stroma caused by herpes simplex virus. Am J Ophthalmol (1966) 0.88
The relationship of the possible allergic response to jellyfish envenomation and serum antibody titers. Toxicon (1983) 0.88
Focus formation and neoplastic transformation by herpes simplex virus type 2 inactivated intracellularly by 5-bromo-2'-deoxyuridine and near UV light. J Virol (1981) 0.88
Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol (1997) 0.87
Swimmer's itch: a cercarial dermatitis. Cutis (1990) 0.87
Cell-mediated immune response to herpes simplex virus: type-specific lymphoproliferative responses in lymph nodes draining the site of primary infection. J Immunol (1976) 0.86
Cowden disease. Report of two additional cases. Br J Dermatol (1975) 0.86
Electrophysiological and hemolytic activity elicited by the venom of the jellyfish Cassiopea xamachana. Toxicon (2001) 0.86
AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). Virology (1997) 0.86
A comparison of the toxinological characteristics of two Cassiopea and Aurelia species. Toxicon (2001) 0.85
Immediate early and functional AP-1 cis-response elements are involved in the transcriptional regulation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). Virus Res (1992) 0.85
Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation. J Gen Virol (1992) 0.85
Cell-mediated sensitization to jellyfish antigens confirmed by positive patch test to Olindias sambaquiensis preparations. J Am Acad Dermatol (1995) 0.85
Diarrhoeal diseases in the White Mountain Apaches: epidemiologic studies. J Diarrhoeal Dis Res (1995) 0.85